Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | September 10, 2026 | September 14, 2026 |
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | EVP, Chief Research Officer | March 10, 2026 | March 12, 2026 |
| Translate Bio, Inc.TBIO · Entity 135439 | Director | September 14, 2021 | September 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,140 |
Reported balance
After 2026-09-10 transaction · row 1
1 source rowRow 1 · 2026-09-10 · Grant · Acquired 6,140 · Balance 6,140 F1: Restricted stock units granted on September 10, 2026. Price not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on September 10, 2026. Price not applicable.
BRISTOL MYERS SQUIBB CO
Report date March 10, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 21,528 |
Ending reported balance
After 2026-03-10 transaction · row 9
9 source rows · reconciled sequenceRow 1 · 2026-03-10 · Exercise / conversion · Acquired 1,107 · Balance 16,946 F1: Represents vesting of one-quarter market share units granted on March 10, 2022. Row 2 · 2026-03-10 · Other · Disposed 124 · Balance 16,822 F2: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Row 3 · 2026-03-10 · Tax withholding · Disposed 436 · Balance 16,386 F3: Shares withheld for payment of taxes upon vesting of awards. Row 4 · 2026-03-10 · Exercise / conversion · Acquired 2,342 · Balance 18,728 F4: Represents vesting of one-quarter market share units granted on March 10, 2023. Row 5 · 2026-03-10 · Other · Disposed 253 · Balance 18,475 F2: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Row 6 · 2026-03-10 · Tax withholding · Disposed 927 · Balance 17,548 F3: Shares withheld for payment of taxes upon vesting of awards. Row 7 · 2026-03-10 · Exercise / conversion · Acquired 14,052 · Balance 31,600 F5: Amount represents distribution of performance shares earned under the 2023-2025 Long-Term Performance Award. Row 8 · 2026-03-10 · Other · Disposed 6,900 · Balance 24,700 F6: Adjustment to award based on the performance factor applied in accordance with the terms of the award and certification of performance results by the Board. Row 9 · 2026-03-10 · Tax withholding · Disposed 3,172 · Balance 21,528 F3: Shares withheld for payment of taxes upon vesting of awards. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2026-03-10 | Direct | 0 |
Reported balance
After 2026-03-10 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-03-10 · Exercise / conversion · Disposed 1,107 · Balance 0 F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F1: Represents vesting of one-quarter market share units granted on March 10, 2022. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2027-03-10 | Direct | 2,342 |
Reported balance
After 2026-03-10 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-03-10 · Exercise / conversion · Disposed 2,342 · Balance 2,342 F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F4: Represents vesting of one-quarter market share units granted on March 10, 2023. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2029-03-10 | Direct | 17,959 |
Reported balance
After 2026-03-10 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-03-10 · Grant · Acquired 17,959 · Balance 17,959 F11: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout. F12: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2026-03-10 | Direct | 0 |
Reported balance
After 2026-03-10 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-03-10 · Exercise / conversion · Disposed 14,052 · Balance 0 F10: Each performance share unit converted into one share of common stock upon distribution in the first quarter of 2026. F5: Amount represents distribution of performance shares earned under the 2023-2025 Long-Term Performance Award. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2029-03-10 | Direct | 26,939 |
Reported balance
After 2026-03-10 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-03-10 · Grant · Acquired 26,939 · Balance 26,939 F13: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBMS Savings and Investment Program | 3,026.38 |
Reported balance
Holding disclosure · report date 2026-03-10 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 3,026.38 F7: Based on recent 401(k) plan statement. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectFamily Trust | 200 |
Reported balance
Holding disclosure · report date 2026-03-10 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 200 F8: Shares held in a family trust, where reporting person is a beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents vesting of one-quarter market share units granted on March 10, 2022.
F2: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor.
F3: Shares withheld for payment of taxes upon vesting of awards.
F4: Represents vesting of one-quarter market share units granted on March 10, 2023.
F5: Amount represents distribution of performance shares earned under the 2023-2025 Long-Term Performance Award.
F6: Adjustment to award based on the performance factor applied in accordance with the terms of the award and certification of performance results by the Board.
F7: Based on recent 401(k) plan statement.
F8: Shares held in a family trust, where reporting person is a beneficiary.
F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%.
F10: Each performance share unit converted into one share of common stock upon distribution in the first quarter of 2026.
F11: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout.
F12: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board.
F13: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board.
Translate Bio, Inc.
Report date September 14, 2021 · Filed September 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.36 · Expires 2029-04-09 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-09-14 · Sale · Disposed 37,800 · Balance 0 F1: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F2: This option was granted on April 10, 2019. The shares underlying this option are scheduled to vest and become exercisable in equal monthly installments, beginning on May 10, 2019 and ending on the three year anniversary of April 10, 2019. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.20 · Expires 2029-06-17 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-09-14 · Sale · Disposed 18,900 · Balance 0 F1: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F3: This option was granted on June 18, 2019. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.33 · Expires 2030-06-15 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-09-14 · Sale · Disposed 18,900 · Balance 0 F1: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F4: This option was granted on June 16, 2020. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.43 · Expires 2031-06-15 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-09-14 · Sale · Disposed 20,000 · Balance 0 F1: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F5: This option was granted on June 16, 2021. This option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
F2: This option was granted on April 10, 2019. The shares underlying this option are scheduled to vest and become exercisable in equal monthly installments, beginning on May 10, 2019 and ending on the three year anniversary of April 10, 2019.
F3: This option was granted on June 18, 2019. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2020.
F4: This option was granted on June 16, 2020. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2021.
F5: This option was granted on June 16, 2021. This option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 14, 2026 22:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 6,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-061940 · wk-form4_1789426499.xml · nonDerivative · entry 1 Plenge Robert M · CIK 0001773367 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,140 F1 · price: Restricted stock units granted on September 10, 2026. Price not applicable. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 26,939 | $0.00 | $0.00 |
DisclosureSEC source: 0001773367-26-000002 · wk-form4_1773346808.xml · derivative · entry 16 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,939 Underlying: Common Stock, $0.10 par value · 26,939 shares Expires 2029-03-10 F13 · derivative.exercise_price: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board. F13 · derivative.exercise_date: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 17,959 | $0.00 | $0.00 |
DisclosureSEC source: 0001773367-26-000002 · wk-form4_1773346808.xml · derivative · entry 15 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,959 Underlying: Common Stock, $0.10 par value · 17,959 shares Expires 2029-03-10 F11 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout. F12 · derivative.exercise_date: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionPerformance Shares · Derivative | 14,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001773367-26-000002 · wk-form4_1773346808.xml · derivative · entry 14 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 14,052 shares Expires 2026-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each performance share unit converted into one share of common stock upon distribution in the first quarter of 2026. F5 · derivative.exercise_date: Amount represents distribution of performance shares earned under the 2023-2025 Long-Term Performance Award. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 2,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001773367-26-000002 · wk-form4_1773346808.xml · derivative · entry 13 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,342 Underlying: Common Stock, $0.10 par value · 2,342 shares Expires 2027-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F4 · derivative.exercise_date: Represents vesting of one-quarter market share units granted on March 10, 2023. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001773367-26-000002 · wk-form4_1773346808.xml · derivative · entry 12 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 1,107 shares Expires 2026-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F1 · derivative.exercise_date: Represents vesting of one-quarter market share units granted on March 10, 2022. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,172 | $60.13 | $190,732.36 |
DisclosureSEC source: 0001773367-26-000002 · wk-form4_1773346808.xml · nonDerivative · entry 9 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,528 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 6,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001773367-26-000002 · wk-form4_1773346808.xml · nonDerivative · entry 8 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,700 F6 · shares: Adjustment to award based on the performance factor applied in accordance with the terms of the award and certification of performance results by the Board. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 14,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001773367-26-000002 · wk-form4_1773346808.xml · nonDerivative · entry 7 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Amount represents distribution of performance shares earned under the 2023-2025 Long-Term Performance Award. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 927 | $60.13 | $55,740.51 |
DisclosureSEC source: 0001773367-26-000002 · wk-form4_1773346808.xml · nonDerivative · entry 6 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,548 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 253 | $0.00 | $0.00 |
DisclosureSEC source: 0001773367-26-000002 · wk-form4_1773346808.xml · nonDerivative · entry 5 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,475 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 2,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001773367-26-000002 · wk-form4_1773346808.xml · nonDerivative · entry 4 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents vesting of one-quarter market share units granted on March 10, 2023. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 436 | $60.13 | $26,216.68 |
DisclosureSEC source: 0001773367-26-000002 · wk-form4_1773346808.xml · nonDerivative · entry 3 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,386 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 124 | $0.00 | $0.00 |
DisclosureSEC source: 0001773367-26-000002 · wk-form4_1773346808.xml · nonDerivative · entry 2 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,822 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001773367-26-000002 · wk-form4_1773346808.xml · nonDerivative · entry 1 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter market share units granted on March 10, 2022. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 35,146 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000072 · wk-form4_1741829979.xml · derivative · entry 20 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,146 Underlying: Common Stock, $0.10 par value · 35,146 shares Expires 2028-03-10 F13 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2028, subject to certification of performance results by the Board. F13 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2028, subject to certification of performance results by the Board. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionPerformance Shares · Derivative | 6,641 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000072 · wk-form4_1741829979.xml · derivative · entry 19 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 6,641 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_price: Each performance share converted into one share of common stock upon distribution in the first quarter of 2025 in accordance with the terms of the award and certification of performance results by the Board. F6 · derivative.exercise_date: Amount represents distribution of performance shares earned under the 2022-2024 Long-Term Performance Award. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 23,431 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000072 · wk-form4_1741829979.xml · derivative · entry 18 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,431 Underlying: Common Stock, $0.10 par value · 23,431 shares Expires 2028-03-10 F10 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout. F11 · derivative.exercise_date: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 2,342 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000072 · wk-form4_1741829979.xml · derivative · entry 17 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,684 Underlying: Common Stock, $0.10 par value · 2,342 shares Expires 2027-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F5 · derivative.exercise_date: Represents vesting of one-quarter market share units granted on March 10, 2023. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000072 · wk-form4_1741829979.xml · derivative · entry 16 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,107 Underlying: Common Stock, $0.10 par value · 1,107 shares Expires 2026-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F4 · derivative.exercise_date: Represents vesting of one-quarter market share units granted on March 10, 2022. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 1,165 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000072 · wk-form4_1741829979.xml · derivative · entry 15 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 1,165 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1 · derivative.exercise_date: Represents vesting of one-quarter market share units granted on March 10, 2021. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,860 | $63.11 | $117,384.60 |
DisclosureSEC source: 0000014272-25-000072 · wk-form4_1741829979.xml · nonDerivative · entry 12 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,839 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 2,449 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000072 · wk-form4_1741829979.xml · nonDerivative · entry 11 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,699 F7 · shares: Adjustment to award based on the performance factor applied in accordance with the terms of the award and certification of performance results by the Board. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 6,641 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000072 · wk-form4_1741829979.xml · nonDerivative · entry 10 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Amount represents distribution of performance shares earned under the 2022-2024 Long-Term Performance Award. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 862 | $63.11 | $54,400.82 |
DisclosureSEC source: 0000014272-25-000072 · wk-form4_1741829979.xml · nonDerivative · entry 9 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,507 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 399 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000072 · wk-form4_1741829979.xml · nonDerivative · entry 8 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,369 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 2,342 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000072 · wk-form4_1741829979.xml · nonDerivative · entry 7 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents vesting of one-quarter market share units granted on March 10, 2023. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 406 | $63.11 | $25,622.66 |
DisclosureSEC source: 0000014272-25-000072 · wk-form4_1741829979.xml · nonDerivative · entry 6 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,426 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 193 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000072 · wk-form4_1741829979.xml · nonDerivative · entry 5 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,832 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000072 · wk-form4_1741829979.xml · nonDerivative · entry 4 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents vesting of one-quarter market share units granted on March 10, 2022. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 482 | $63.11 | $30,419.02 |
DisclosureSEC source: 0000014272-25-000072 · wk-form4_1741829979.xml · nonDerivative · entry 3 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,918 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 80 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000072 · wk-form4_1741829979.xml · nonDerivative · entry 2 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,400 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 1,165 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000072 · wk-form4_1741829979.xml · nonDerivative · entry 1 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter market share units granted on March 10, 2021. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 01:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 23,220 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000074 · wk-form4_1710292877.xml · derivative · entry 18 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,220 Underlying: Common Stock, $0.10 par value · 23,220 shares Expires 2027-03-10 F15 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2027. F15 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2027. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 01:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionPerformance Shares · Derivative | 6,985 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000074 · wk-form4_1710292877.xml · derivative · entry 17 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 6,985 shares Expires 2024-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2024, subject to a Total Shareholder Return. F14 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2024, subject to a Total Shareholder Return. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 01:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 15,480 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000074 · wk-form4_1710292877.xml · derivative · entry 16 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,480 Underlying: Common Stock, $0.10 par value · 15,480 shares Expires 2028-03-10 F10 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F12 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 01:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherMarket Share Units · Derivative | 2,342 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000074 · wk-form4_1710292877.xml · derivative · entry 15 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,026 Underlying: Common Stock, $0.10 par value · 2,342 shares Expires 2027-03-10 F10 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F13 · shares: Represents the cancellation of one-quarter of market share units granted on March 10, 2023 due to the 80% minimum payout factor not being achieved. F12 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 01:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherMarket Share Units · Derivative | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000074 · wk-form4_1710292877.xml · derivative · entry 14 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,214 Underlying: Common Stock, $0.10 par value · 1,107 shares Expires 2026-03-10 F10 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F11 · shares: Represents the cancellation of one-quarter of market share units granted on March 10, 2022 due to the 80% minimum payout factor not being achieved. F12 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 01:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 1,164 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000074 · wk-form4_1710292877.xml · derivative · entry 13 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,165 Underlying: Common Stock, $0.10 par value · 1,164 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2021. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 01:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 994 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000074 · wk-form4_1710292877.xml · derivative · entry 12 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 994 shares Expires 2024-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2020. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 01:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,436 | $53.79 | $77,242.44 |
DisclosureSEC source: 0000014272-24-000074 · wk-form4_1710292877.xml · nonDerivative · entry 9 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,315 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 01:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 2,431 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000074 · wk-form4_1710292877.xml · nonDerivative · entry 8 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,751 F6 · shares: Adjustment to Award based on the performance factor applied in accordance with the terms of the Award and certification of performance results by the Board. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 01:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 6,985 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000074 · wk-form4_1710292877.xml · nonDerivative · entry 7 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Amount represents distribution of performance shares earned under the 2021-2023 Long-Term Performance Award. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 01:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 283 | $53.79 | $15,222.57 |
DisclosureSEC source: 0000014272-24-000074 · wk-form4_1710292877.xml · nonDerivative · entry 6 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,197 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 01:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 201 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000074 · wk-form4_1710292877.xml · nonDerivative · entry 5 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,480 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 01:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 1,164 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000074 · wk-form4_1710292877.xml · nonDerivative · entry 4 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2021. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 01:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 246 | $53.79 | $13,232.34 |
DisclosureSEC source: 0000014272-24-000074 · wk-form4_1710292877.xml · nonDerivative · entry 3 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,517 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 01:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 157 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000074 · wk-form4_1710292877.xml · nonDerivative · entry 2 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,763 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 01:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 994 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000074 · wk-form4_1710292877.xml · nonDerivative · entry 1 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2020. Read SEC document |
| December 02, 2023 Filed Dec 5, 2023 23:23 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 616 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-23-000195 · wk-form4_1701818599.xml · derivative · entry 4 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 616 shares Expires 2023-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: The restricted stock unit vests in four equal annual installments beginning on December 2, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.